Board member in Alligator Bioscience resigns at his own request
Lund, Sweden, April 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company's Board member Carl Borre ...
Alligator Bioscience AB: Interim report January–March 2021
High activity during the first quarter ”So far, 2021 has been characterized by high activity, with a research collaboration that validates o ...
Notice of annual general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 (“Alligator”), are invited to the annual general meeting to be held on Tue ...
The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding C ...
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Lund, Sweden, April 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research coll ...
Alligator Bioscience postpones the Annual General Meeting to June 1, 2021
Lund, Sweden, April 3, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the board of directors has decided to post ...
Alligator Bioscience appoints Søren Bregenholt as new CEO
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...
Alligator Bioscience publishes Annual Report for 2020
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...
Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR
Lund, Sweden, March 11, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that an abstract for a poster presentation at ...